S. Karger AG

S. Karger AG is the Swiss scientific publisher behind the 2012 volume Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Its decisive role is institutional rather than clinical: it provided the publishing framework through which research on hepatitis C, chronic kidney disease, hemodialysis, renal pathology, and transplantation was gathered, edited, and made available to an international medical readership.

Identity and Publication Role

S. Karger AG published the volume in 2012, with copyright credited to the company and its Basel address identified as P.O. Box, CH-4009 Basel, Switzerland. The book also records the publisher’s website and states that it was printed in Germany on acid-free, non-aging paper, presenting the work as a durable scholarly reference rather than an ephemeral clinical communication.

The volume’s subject reflects the publisher’s specialist medical orientation. It treats hepatitis C as a systemic disease capable of affecting the liver as well as producing autoimmune, dermatological, and renal complications. The publication therefore occupies the intersection of hepatology, nephrology, dialysis, and transplantation, disciplines that require coordination between laboratory diagnosis, pathology, antiviral treatment, infection control, and long-term outcome assessment.

Support for the Editorial Project

Jose M. Morales described approaching Dr. Jadoul, Dr. Rostaing, and Dr. Roth three years after the publication of the KDIGO clinical practice guidelines on hepatitis C in chronic kidney disease. S. Karger AG accepted the proposal as a new volume of Contributions in Nephrology, enabling the project to become a coordinated review of developments in HCV infection, renal disease, dialysis problems, renal transplantation, and renal complications in patients with HIV infection.

The book credits the publisher with accepting the editors’ suggestion and acknowledges Karger Publishers for its contribution to making the undertaking possible. The project assembled international authors, many of them participants in KDIGO, whose work had helped establish knowledge about HCV in patients with chronic kidney disease. In that setting, S. Karger AG functioned as the institutional bridge between a guideline-making network and a book-length synthesis of its clinical concerns.

Knowledge Distributed Through the Volume

The material issued under the S. Karger AG imprint preserves a period of rapid change in HCV medicine. It describes a worldwide burden estimated at about 170 million infected people, the need to distinguish anti-HCV antibodies from detectable HCV RNA, and the use of noninvasive fibrosis assessment, including FibroScan, alongside or instead of liver biopsy. It also records the transition from pegylated interferon and ribavirin toward direct-acting antiviral drugs, including telaprevir and boceprevir, whose first-generation triple therapies increased sustained virologic response rates in genotype 1 infection.

The publication extends that diagnostic and therapeutic framework into renal medicine. It presents HCV as a major cause of mixed cryoglobulinemia and cryoglobulinemic glomerulonephritis, with manifestations that may include proteinuria, hematuria, reduced eGFR, nephritic syndrome, and nephrotic syndrome. It also explains how HCV-related immune-complex disease can appear in renal allografts as de novo membranoproliferative glomerulonephritis, sometimes alongside transplant glomerulopathy, making the book relevant to both disease classification and post-transplant management.

Clinical and Policy Significance

S. Karger AG’s volume also carries recommendations whose practical force depends on distinctions made by contemporary guidelines. Chronic infection is established through both anti-HCV positivity and HCV RNA positivity, while antibody positivity alone does not distinguish resolved from active infection. In kidney-transplant candidates, the book emphasizes systematic screening, with enzyme immunoassay followed by nucleic-acid testing in low-prevalence settings and nucleic-acid testing as the initial approach where prevalence is high.

The same institutional publication records the changing understanding of HCV transmission in hemodialysis. As blood screening improved and the risk of post-transfusion hepatitis C fell from about 0.5 percent per blood unit in the 1980s to approximately 0.0001 percent in the United States, attention shifted toward infection-control failures within dialysis units. The KDIGO workgroup concluded that dedicated dialysis machines were not recommended and that isolating HCV-infected patients was not an adequate alternative to strict infection-control procedures.

The volume further translates treatment evidence into renal practice. Because kidney disease affects the handling of interferon and ribavirin, and because ribavirin accumulation can produce severe anemia, treatment must be individualized; ribavirin is contraindicated when creatinine clearance is below 50 ml/min. For acute HCV infection in dialysis patients, KDIGO and AASLD recommendations support observing for between eight and twelve weeks to allow spontaneous resolution before committing patients to antiviral treatment. Through these details, the publisher’s book makes guidelines, laboratory thresholds, pathological distinctions, and therapeutic risks available within one connected reference work.

Material and Intellectual Legacy

The publication’s physical durability and its intellectual breadth reinforce one another. Acid-free, non-aging paper gives the volume a long scholarly life, while its contents document a medical field moving from the recognition of HCV as the principal cause of non-A non-B hepatitis toward molecular diagnosis, genotype-based therapy, direct-acting antivirals, and increasingly precise accounts of renal injury.

S. Karger AG is therefore significant not because it appears as a clinical actor in the disease narrative, but because it provides the durable scholarly container in which that narrative is organized. The volume links global epidemiology, antibody and RNA testing, fibrosis assessment, cryoglobulinemic disease, dialysis transmission, antiviral pharmacology, transplantation, and graft pathology. Its publishing role turns dispersed investigations and guideline recommendations into a sustained reference for understanding how HCV reshapes renal medicine.